Tumor Targeting of a STING Agonist by Means of an ADC Induces Anti-Tumor Immune Responses & Immunological Memory
Time: 4:40 pm
day: Day One
Details:
- Mersana has developed the Immunosynthen platform to enable tumor-targeted delivery of a STING agonist by means of an ADC
- Demonstrating how targeted STING-agonist ADCs induce potent anti-tumor immune responses and immunological memory
- Understanding how targeted STING-agonist ADCs cause significantly more anti-tumor activity and dramatically less induction of systemic cytokines than intravenously administered free STING agonist
Speakers:
Marc Damelin is Executive Director, Head of Biology at Mersana Therapeutics, where he is focused on ADC discovery and development for oncology. Prior, he spent 10 years at Pfizer, where he led ADC discovery teams, oversaw the ADC portfolio and mentored two postdoctoral fellows. He is the Editor of the book “Innovations for Next-Generation Antibody-Drug Conjugates” published…Read more